Sermorelin: A Growth Hormone Secretagogue Studied for Age-Related GH Decline

Compounded sermorelin is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness, or quality. A patient-specific prescription is required. Sermorelin may be prescribed when clinically appropriate for an individual patient, and we do not claim equivalence to any FDA-approved drug. Counseling, monitoring, and eligibility are determined by the clinician. Sermorelin Rx is not available in all 50 states.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health facilitates access to compounded sermorelin through licensed healthcare providers and compounding pharmacy partners. Compounded sermorelin is a prescription medication available only by prescription. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

You sleep eight hours and wake up tired. You train consistently and recover slower every year. Your doctor says your labs are normal. That disconnect can have many causes; one studied factor is a hormone axis that standard bloodwork rarely evaluates: the growth hormone cascade, and the pituitary's declining ability to sustain it.

Sermorelin is a synthetic peptide studied for its influence on that axis. Here is how it works, what the research shows, and how to know whether it is relevant to you.

Key takeaways

• Regulatory Status: FDA-approved in 1990 as a diagnostic test of pituitary growth hormone secretion and in 1997 for idiopathic growth hormone deficiency in children; discontinued in 2008, with both approvals withdrawn in 2009. Not currently FDA-approved for any use. Available as a compounded prescription through licensed providers and licensed 503A compounding pharmacies.
• Research Stage: Clinically studied in the GHRH secretagogue class; available through compounding
• Availability: Prescription only, when clinically appropriate. Sermorelin Rx is not available in all 50 states.
• Compound reference: View compound reference data (PubChem CID 16132413) — FDA approvals withdrawn 2009; no current DailyMed label
• How it works: Binds GHRH receptors on the anterior pituitary, stimulating pulsatile growth hormone release while preserving the body's natural feedback loop.
• What the research shows: Tesamorelin trials (a related GHRH analog) reported lower visceral fat and higher lean mass over 26–52 weeks; sermorelin-specific data are limited.

What is sermorelin?

Sermorelin acetate is a synthetic 29-amino-acid peptide identical to the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on the anterior pituitary, triggering pulsatile growth hormone release while preserving the hypothalamic feedback loop that is thought to limit supraphysiological GH levels (background on somatostatin modulation of GHRH pathways supports this regulatory mechanism). This physiological braking mechanism is what distinguishes it from direct exogenous human growth hormone (HGH).

Sermorelin was first characterized in the early 1980s and received FDA approval in 1990 and 1997: first as a diagnostic test of pituitary growth hormone secretion, then indicated for idiopathic growth hormone deficiency in children. The manufacturer discontinued the product in 2008, both approvals were withdrawn in 2009, and FDA later determined that the discontinued GEREF products were not withdrawn from sale for reasons of safety or effectiveness. No current FDA-approved sermorelin product exists. Compounding pharmacies may prepare sermorelin under Section 503A with a patient-specific prescription.

Sermorelin and the GHRH class evidence

Sermorelin's clinical evidence base is inseparable from a closely related compound: tesamorelin. Tesamorelin is a GHRH analog with an added trans-3-hexenoic acid group that extends its plasma half-life. It is FDA-approved for HIV-associated lipodystrophy. Both compounds bind the same GHRH receptor on the anterior pituitary and operate through the same pulsatile GH release mechanism. Where sermorelin-specific data are limited, the tesamorelin evidence base provides a reference point for what GHRH receptor activation has shown. The distinction is noted throughout this article where it applies.

What the GHRH class research shows

1. Visceral fat: tesamorelin trials

Growth hormone drives lipolysis, particularly in visceral adipose tissue. GHRH receptor activation stimulates pulsatile GH release, which in turn promotes fatty acid mobilization from abdominal fat stores. The controlled trial evidence for this effect comes from the GHRH class: a 2007 RCT by Falutz and colleagues in the New England Journal of Medicine randomized 412 HIV-infected patients to tesamorelin 2 mg subcutaneous daily or placebo for 26 weeks and found that visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% with placebo (p < 0.001), with a concurrent 50 mg/dL reduction in triglycerides (p < 0.001 vs. placebo). A 2010 pooled analysis by the same team in JCEM combined two phase 3 trials (N=806; tesamorelin 2 mg subcutaneous daily vs. placebo, 2:1 randomization, 26-week primary phase with 26-week extension) and found visceral adipose tissue reduced by approximately 15.4% at 26 weeks versus placebo, sustained through 52 weeks without significant glucose perturbation. A 2012 RCT by Makimura and colleagues in JCEM randomized 60 abdominally obese adults with reduced GH secretion to tesamorelin 2 mg subcutaneous daily or placebo for 12 months and found a net 19% reduction in visceral adipose tissue versus placebo, alongside a net 6% improvement in carotid intima-media thickness, a net triglyceride reduction of 38 mg/dL versus placebo (-26 ± 16 vs. +12 ± 8 mg/dL), and a significant reduction in log CRP (-0.17 ± 0.04 vs. -0.03 ± 0.05 mg/L), without aggravating glucose. These trials used tesamorelin; sermorelin activates the same receptor but controlled sermorelin-specific body composition data remain limited.

2. Lean mass: tesamorelin trials

GH stimulates protein synthesis by promoting amino acid uptake (as noted in an editorial commentary on GH signaling) and IGF-1 secretion; IGF-1 in turn activates mTOR signaling in muscle tissue. These pathways are engaged by compounds that stimulate pulsatile GH release through the GHRH receptor. A 2019 secondary analysis by Adrian and colleagues in the Journal of Frailty and Aging examined CT scans from 341 HIV-infected adults (193 tesamorelin responders, 148 placebo) who received tesamorelin 2 mg subcutaneous daily for 26 weeks and found that tesamorelin significantly increased truncal muscle density by 1.56 to 4.86 Hounsfield units across four muscle groups versus placebo (all p < 0.005), with concurrent increases in lean muscle area of 0.64 to 1.08 cm² across four truncal muscle groups versus placebo. A 2026 meta-analysis by Badran and Helal in Obesity Research and Clinical Practice, pooling five RCTs of tesamorelin 2 mg subcutaneous daily versus placebo over 26 to 52 weeks, confirmed a significant increase in lean body mass (mean difference 1.42 kg, 95% CI 1.13–1.71, p < 0.001) alongside reductions in visceral adipose tissue, trunk fat, and hepatic fat without serious adverse effects or glucose perturbation. As with body composition, these findings come from tesamorelin trials; the shared receptor mechanism supports biological plausibility for sermorelin but direct extrapolation requires that caveat.

3. IGF-1: GHRH and sermorelin studies

Reduced endogenous hypothalamic GHRH output appears to contribute to somatopause — the gradual reduction in GH secretion beginning in early adult life — as a 1999 study by Russell-Aulet and Jaffe in JCEM found. A 1989 study by Iovino, Monteleone, and Steardo in JCEM administered 100 mcg intravenous GHRH-40 every 2 days for 12 days to 7 healthy men aged 65–78 in a double-blind placebo-controlled design, finding that this priming regimen significantly restored the GH response at 30, 60, and 90 minutes after an acute GHRH challenge compared to values seen after placebo priming — notable given that baseline peak GH in the elderly group was only 3.1 ± 1.0 ng/mL versus 21.6 ± 5.0 ng/mL in young controls. A 2017 retrospective study by Sigalos and Pastuszak reviewed 14 hypogonadal men (mean age 33.2 years) on testosterone therapy who received a combination of GHRP-2, GHRP-6, and sermorelin at 100 mcg three times daily for a mean of 134 days, finding that serum IGF-1 levels rose from a baseline of 159.5 ng/mL to 239.0 ng/mL — a 50% increase (p < 0.0001). The 1999 sermorelin monograph in BioDrugs by Prakash and Goa describes this mechanism for sermorelin specifically.

4. Sleep: GHRH infusion studies

GHRH has documented sleep-promoting effects in controlled studies. A 1993 study in the American Journal of Physiology by Kerkhofs and Van Cauter administered intravenous GHRH at 0.3 mcg/kg to 8 healthy young men in a crossover design and found that GHRH given during late sleep produced an almost 10-fold increase in slow-wave sleep versus placebo, without disrupting sleep continuity. A separate 1992 study in Neuroendocrinology by Steiger and colleagues administered four pulsatile 50 mcg intravenous boluses of GHRH versus placebo to 7 healthy men and found that slow-wave sleep increased from 14.0% to 20.2% of total sleep time (a 44% relative increase versus placebo) alongside elevated nocturnal GH secretion and blunted cortisol release. A 1999 study in Psychoneuroendocrinology by Perras and Marshall administered 300 mcg intranasal GHRH versus placebo in a double-blind crossover design to 12 young and 11 elderly healthy men and found that intranasal GHRH increased both slow-wave sleep and REM sleep — concentrated in the second half of the night — with concurrent modulation of cortisol and GH secretion, and these effects did not depend on subject age. A 1997 study in Neurobiology of Aging by Guldner and Schier administered four pulsatile 50 mcg intravenous boluses of GHRH versus placebo to 13 healthy seniors (mean age 69.3 years) and found significantly reduced nocturnal awakenings and a longer first non-REM sleep period compared to placebo, though the magnitude of these effects was substantially attenuated relative to young adults tested with the same protocol, which the authors interpreted as reduced GHRH efficacy with aging. The relationship between GH pulsatility and slow-wave sleep is bidirectional: GH is primarily secreted during slow-wave sleep, and GHRH signaling may promote both.

5. Lipids: tesamorelin trials

GH influences lipid metabolism through two primary pathways: promoting lipolysis in adipose tissue and affecting hepatic very-low-density lipoprotein (VLDL) production. Restoring pulsatile GH release through GHRH receptor activation engages both. In the GHRH class trials, the Makimura JCEM RCT found significant reductions in triglycerides and CRP compared to placebo, and the Falutz NEJM trial observed favorable lipid changes alongside body composition improvements. These data come from tesamorelin; sermorelin-specific lipid trial data remain limited, though the shared mechanism supports biological plausibility.

Join 150,000+ others building better health

Get the science behind better health, every week.

SubscribeSigning up...

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

Sermorelin vs. exogenous HGH: Key differences

Sermorelin stimulates the body's own GH production; exogenous HGH bypasses the pituitary entirely. This distinction preserves the negative feedback loop that is thought to limit excess GH levels.

When HGH is injected directly, it elevates GH levels regardless of what the hypothalamic-pituitary axis is signaling. There is no physiological ceiling. Supraphysiological GH exposure is associated with adverse effects including fluid retention, joint pain, potential insulin resistance, and long-term risk considerations. Sermorelin works upstream: it prompts the pituitary to release GH in its natural pulsatile pattern, and the hypothalamus retains the ability to reduce that signal via somatostatin (research on somatostatin modulation provides context for this feedback pathway) when levels are sufficient. This regulatory architecture is thought to limit the risk of runaway GH elevation; no head-to-head safety trials compare sermorelin with HGH.

Practically, sermorelin requires an intact and responsive pituitary. Individuals with significant pituitary damage or primary GH deficiency confirmed by stimulation testing may not respond adequately. Exogenous HGH bypasses this requirement. HGH is FDA-approved for adult GH deficiency confirmed by stimulation testing; sermorelin has no current FDA-approved indication. As of September 2026, GHRH analogues, including sermorelin, are on the 2026 WADA Prohibited List and are prohibited at all times, in and out of competition.

Sermorelin formulations

Compounded sermorelin is prepared for two routes. Subcutaneous injection is more bioavailable than sublingual delivery. Sublingual preparations, dissolved under the tongue, provide a needle-free alternative with lower absorption. Bioavailability via the sublingual route is lower than subcutaneous injection. For context on non-injected routes, a 1986 intranasal and injection dose-response study by Vance and Evans in Clinical Pharmacology and Therapeutics tested [Nle27]GHRH(1-29)-NH2 in healthy men (N=10 intravenous, N=8 subcutaneous, N=5 intranasal) across intravenous doses of 0.25 to 10 mcg/kg, subcutaneous doses, and intranasal doses up to 50 mcg/kg and found that intravenous delivery at 1–2 mcg/kg produced maximal GH peaks of approximately 90 mU/L, while intranasal delivery required roughly 50-fold higher doses to match that response due to 3–5% mucosal bioavailability versus injection. Providers determine the appropriate formulation based on clinical context, patient preference, and therapeutic objectives.

How providers evaluate sermorelin candidacy

Providers typically evaluate sermorelin candidates based on IGF-1 levels below the age-adjusted reference range and a clinical assessment. A 2025 review by Fernandez-Garza and Guillen-Silva in Frontiers in Aging summarizes the rationale and the evidence gaps, noting that long-term safety and efficacy in healthy aging adults remain areas of active research. Sermorelin requires a prescription from a licensed provider and is not available over the counter.

Who should not use sermorelin

A licensed provider will evaluate individual risk factors before prescribing. The following are generally considered contraindications or conditions requiring additional clinical scrutiny:

• Active malignancy or personal history of cancer — GH's pro-proliferative signaling may theoretically stimulate cell growth; sermorelin use has not been studied in active cancer populations
• Diabetes mellitus or clinically significant insulin resistance — GH counter-regulates insulin; elevated GH can worsen glycemic control in susceptible individuals
• Active intracranial lesions or a history of pituitary tumor — sermorelin's pituitary-stimulating mechanism requires clinical evaluation in this context
• Pregnancy or breastfeeding — safety in these populations has not been established
• Known hypersensitivity to sermorelin acetate, mannitol (a common excipient in compounded formulations), or any component of the formulation
• Hypothyroidism, if untreated — in people with hypothyroidism, the GH response to GHRH is blunted and recovers once thyroid levels return to normal; providers typically evaluate thyroid status before initiating sermorelin therapy

Side effects and safety considerations

The sermorelin safety profile is characterized primarily in the 1999 Prakash and Goa monograph and in GHRH class studies. Most reported adverse effects are mild, dose-dependent, and often diminish within the first weeks of use.

Common (reported in clinical studies):

• Injection-site redness, swelling, or pain — typically transient
• Flushing — transient and generally mild; more common at higher doses
• Headache — reported in early-stage use; often resolves spontaneously
• Somnolence or drowsiness — consistent with GHRH's reported effects on sleep

Less common but reported:

• Fluid retention or peripheral edema — attributable to GH's effects on sodium and water reabsorption; monitor in individuals with cardiovascular or renal conditions
• Joint pain or stiffness (arthralgia) — associated with GH axis activity; generally reversible; contact your provider
• Dizziness — contact your provider if persistent
• Glucose elevation — particularly in individuals with pre-existing insulin resistance; baseline and follow-up glucose monitoring is standard

Is sermorelin legal?

As of September 2026, sermorelin is not FDA-approved for any indication. Both original approvals, diagnostic and pediatric, were withdrawn in 2009 after the manufacturer discontinued the product in 2008. No current FDA-reviewed clinical indication exists. Sermorelin is not available over the counter.

Sermorelin has no United States Pharmacopeia monograph, and it does not appear on the FDA's bulk drug substance category lists. Licensed 503A compounding pharmacies can prepare and dispense it with a patient-specific prescription from a licensed provider under Section 503A of the Federal Food, Drug, and Cosmetic Act. Because no FDA-approved sermorelin product exists and it has no currently approved use in humans, all use is outside any FDA-approved indication.

GHRH analogues, including sermorelin, are on the 2026 WADA Prohibited List as growth hormone releasing factors and are prohibited at all times, in and out of competition. Athletes subject to anti-doping testing should consult their governing body or a qualified anti-doping advisor before use.

Test first, then decide

The principle of testing first, then deciding, is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not in symptoms alone.

Frequently asked questions

What is the difference between sermorelin and HGH?

Sermorelin stimulates the pituitary to release growth hormone in a pulsatile, physiologically regulated pattern. Exogenous HGH delivers GH directly, bypassing the hypothalamic-pituitary feedback loop entirely. This means HGH can produce supraphysiological GH levels without a natural braking mechanism. Sermorelin preserves that feedback regulation, which is thought to limit the risk of excess GH exposure. HGH is FDA-approved for confirmed adult GH deficiency; sermorelin has no current FDA-approved indication and is available only through compounding.

Does sermorelin suppress natural growth hormone production?

It is not expected to, based on its mechanism. Sermorelin operates by stimulating the pituitary's own GH release, not by supplying exogenous GH. Because it preserves the hypothalamic feedback loop, the body retains the ability to reduce GH output via somatostatin when levels are adequate. This physiological self-regulation distinguishes sermorelin from exogenous HGH, which can suppress the pituitary's natural output over time through negative feedback from circulating GH and IGF-1.

How quickly does IGF-1 change on sermorelin?

In one retrospective study, IGF-1 levels rose over several months of consistent use of sermorelin with GHRP-2 and GHRP-6. Response varies based on baseline IGF-1 levels, pituitary responsiveness, and individual physiology. Sermorelin-specific data on body composition, sleep, and recovery timelines are limited.

How do sermorelin injections and troches differ?

Subcutaneous injections offer higher bioavailability and more consistent GH stimulation. Sublingual troches are a needle-free alternative with lower absorption. Clinical evidence for the GHRH class is based primarily on injectable formulations; sublingual data are more limited. The appropriate formulation depends on clinical context, patient preference, and provider assessment.

Is sermorelin FDA-approved?

Sermorelin was FDA-approved in 1990 as a diagnostic test of pituitary growth hormone secretion and in 1997 as indicated for idiopathic growth hormone deficiency in children. The manufacturer discontinued it in 2008, and FDA later determined that the discontinued GEREF products were not withdrawn from sale for reasons of safety or effectiveness. There is no currently FDA-approved sermorelin product. As of September 2026, sermorelin is available only as a compounded prescription through licensed 503A compounding pharmacies with a patient-specific prescription from a licensed provider. It has no currently approved use in humans, so all use is outside any FDA-approved indication.

IMPORTANT SAFETY INFORMATION

Sermorelin is not currently FDA-approved for any indication. It was FDA-approved in 1990 for diagnostic use and in 1997 for idiopathic growth hormone deficiency in children; the manufacturer discontinued it in 2008, both approvals were withdrawn in 2009, and FDA determined that the discontinued GEREF products were not withdrawn from sale for reasons of safety or effectiveness. Sermorelin has no USP monograph; licensed 503A compounding pharmacies may prepare it, and all use is outside any FDA-approved indication. Compounded sermorelin is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness, or quality. A patient-specific prescription is required. Sermorelin Rx is not available in all 50 states. Clinical evidence cited on this page draws primarily from the GHRH analog class (including tesamorelin trials); results may not be directly transferable to compounded sermorelin. Superpower is a technology platform; Superpower does not prescribe or dispense medications.

Contraindications: active malignancy or cancer history; diabetes or significant insulin resistance; active intracranial lesions or pituitary tumor history; pregnancy and breastfeeding; untreated hypothyroidism; known hypersensitivity to sermorelin or mannitol.

Common side effects: injection site redness/swelling, flushing, headache, drowsiness.

Less common: fluid retention or edema, joint pain (arthralgia), dizziness, glucose elevation in individuals with pre-existing insulin resistance.

GHRH analogues, including sermorelin, are on the 2026 WADA Prohibited List, prohibited in and out of competition.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health facilitates access to compounded sermorelin through licensed healthcare providers and compounding pharmacy partners. Compounded sermorelin is a prescription medication available only by prescription. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.